NCT00064467

Lethargic Depression Study

An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 268 (planned)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.

Detailed description

A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest

Conditions

• Epilepsy
• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	Extended-release bupropion (HCl)

Timeline

• Start date: 2003-06-01
• Primary completion: 2005-05-01
• Completion: 2005-05-01
• First posted: 2003-07-10
• Last updated: 2017-05-30

Locations

24 sites across 1 country: United States